In studies on mouse colon adenocarcinoma cells MC38 and fibrosarcoma tumor cells MCA205, Li and colleagues found that HDAC3 inhibitors (such as vorinostat and romidepsin) can suppress the expression of CXCL9, CXCL10, and CXCL11 by directly affecting the binding in the promoter region. Here, HDAC3 is linked to neoplasm.